

## Supplemental File 2: Characteristics of included studies

Study (Reference)	Patients (n)	Centers	Clinical setting	Age (y) <sup>a</sup>	Male Sex (%)	Colchicine Dose (mg/d)	Control	FU <sup>b</sup> (y)
<b>Studies in patients with high cardiovascular risk</b>								
Deftereos 2013[12]	222	Single	PCI/CVD	64	65	2x 0.5	Placebo	0.5
Deftereos 2014[22]	279	Single	Heart failure	67	67	1-2x 0.5 <sup>c</sup>	Placebo	0.5
Nidorf 2013[11]	532	Single	PCI/CVD	67	89	0.5	Usual care <sup>d</sup>	3
O'Keefe 1992[10]	197	Single	PCI/CVD	61	86	2x 0.6	Placebo	0.5
<b>Other studies</b>								
Adhami 1998[40]	52	Single	Liver disease	54	87	1 <sup>e</sup>	Placebo	11
Almasio 2000[41]	90	Multi	PBC	55	10	1	Placebo <sup>f</sup>	3
Antoniou 2006[46]	50	Multi	Other	68	84	1	IFN-gamma <sup>g</sup>	2.1
Bodenheimer 1988[28]	57	n.r.	PBC	52	9	2x 0.6	Placebo	2.2
Buligescu 1989[31]	180	n.r.	Liver disease	n.r.	n.r.	1	"Conventional therapy"	3
Colman 1998[39]	129	n.r.	Liver disease	n.r.	n.r.	1	Placebo	3.8
CoPilot 2008[43]	555	n.r.	Liver disease	51	70	2x 0.6	Peg-IFN-alpha	2
CORE 2005[50]	84	Single	Other	54	35	1-2x 0.5 <sup>b</sup>	Usual care <sup>ch</sup>	1.7
CORP 2011[51]	120	Multi	Other	48	46	0.5-1 <sup>b</sup>	Placebo <sup>i</sup>	2
CORP-2 2014[49]	240	Multi	Other	49	50	1-2x 0.5 <sup>b</sup>	Placebo	1.7
Cortez-Pinto 2002[42]	62	Single	Liver disease	54	89	1 <sup>d</sup>	Placebo	3.4
Douglas 1998[38]	26	Single	Other	68	77	0.6-1.2 <sup>j</sup>	Prednisone	2.5
Ikeda 1996[48]	22	Single	PBC	61	14	1	Usual care <sup>ce</sup>	2
Kaplan 1986[25]	60	Single	PBC	n.r. <sup>k</sup>	5	2x 0.6	Placebo	2
Kaplan 1999[44]	87	Single	PBC	51	6	2x 0.6	Methotrexate <sup>l</sup>	10
Kershenobich 1976[23]	28	n.r.	Liver disease	n.r.	n.r.	1 <sup>d</sup>	Placebo	2
Kershenobich 1988[29]	100	Single	Liver disease	51	50	1 <sup>d</sup>	Placebo	14
Kyle 1985[24]	101	Single	Other	63	58	2x 0.6 <sup>m</sup>	Melphalan/Prednisone	5
Kyle 1997[37]	148	n.r.	Other	64	n.r.	2x 0.6	Usual care <sup>cn</sup>	9
Lin 1996[35]	66	Single	Liver disease	40	88	1 <sup>d</sup>	Usual care <sup>c</sup>	4
Lukina 1995[52]	54	n.r.	Other	n.r.	n.r.	1-2	Dimethyl sulfoxide	2 or 7 <sup>o</sup>
Morgan 2005[45]	549	Multi	Liver disease	56	98	2x 0.6	Placebo	6
Muntoni 2010[47]	74	Single	Liver disease	53	62	1	"usual treatment for cirrhosis"	4
Nikolaidis 2006[53]	38	Single	Liver disease	51	61	1 <sup>d</sup>	Usual care <sup>c</sup>	1
Olsson 1995[34]	84	Multi	PSC	42	67	1	Placebo	3
Parise 1995[69]	41	Single	Liver disease	49	88	1	Placebo	1
Paulus 1974[54]	52	Multi	Other	53	100	3x 0.5	Placebo <sup>p</sup>	0.5
Poupon 1996[36]	74	Multi	PBC	54	15	1 <sup>d</sup>	Placebo <sup>e</sup>	2
Raedsch 1992[55]	28	Single	PBC	54	0	1	Placebo <sup>e</sup>	2
Reinhardt 1986[26]	74	Single	Liver disease	n.r.	n.r.	4x 0.25 <sup>d</sup>	Placebo	3
Trinchet 1989[30]	67	Single	Liver disease	52	57	1	Placebo	0.5
Vuoristo 1995[33]	90	Multi	Liver disease	57	14	2x 0.5	Placebo	2
Wang 1994[32]	100	Single	Liver disease	60	94	1	Placebo	2.2
Warnes 1987[27]	64	Single	PBC	n.r.	n.r.	2x 0.5	Placebo	1.5
Yurdakul 2001[21]	116	Single	Other	27	53	2-4x 0.5 <sup>b</sup>	Placebo	2

CVD: cardiovascular disease; d: day; IFN: interferon; m: month; multi: multicenter; n.r.: not reported; PBC: primary biliary cirrhosis; PCI: percutaneous coronary intervention; single: single center; y: years

<sup>a</sup> Age is reported as mean in all but three studies: Antoniou 2006, Kyle 1985, and Nikolaidis 2006 reported median age.

<sup>b</sup> Longest mean follow-up-period for a review-relevant outcome

<sup>c</sup> Weight adjusted maintenance dose

<sup>d</sup> We assume usual care, but this was not explicitly reported

<sup>e</sup> 5 days per week

<sup>f</sup> Ursodeoxycholic acid in both groups

<sup>g</sup> Prednisolone in both groups

<sup>h</sup> Aspirin in both groups

<sup>i</sup> Aspirin or Ibuprofen in both groups

<sup>j</sup> As tolerated

<sup>k</sup> 80% > 50 years

<sup>l</sup> Ursodeoxycholic acid in both groups after 2 years

<sup>m</sup> Increased in 0.6 mg steps (as tolerated). Median dose 1.5 mg/d

<sup>n</sup> Melphalan and Prednisone in both groups

<sup>o</sup> 2 years in Colchicine group, 7 years in control group

<sup>p</sup> Probenecid in both groups